Search

Search Constraints

You searched for: Author/Creator Hayata, Atsushi

Search Results

1. CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50. Issue 1 (27th November 2020)

2. Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency department. Issue 1 (1st May 2021)

3. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. (January 2018)

4. Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71–74]. (December 2018)

5. Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system. (30th January 2020)

7. Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer. (19th November 2019)

8. Impact of pre‐existing interstitial lung abnormal shadow on lung injury development and severity in patients of non‐small cell lung cancer treated with osimertinib. (17th April 2022)

9. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors. Issue 5 (17th March 2020)

10. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. (June 2019)